Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects

Tumor Biology

Volumn 37, Issue 6, 2016, Pages 8425-8435

  Yan, Cihui ^a   Song, Xinmiao ^a   Yu, Wenwen ^a   Wei, Feng ^a   Li, Hui ^a   Lv, Mengguo ^a   Zhang, Xinwei ^a,b   Ren, Xiubao ^a,b  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

CCR2; Lung cancer; MCP 1; Mesenchymal stem cell; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CCR2; ISOLEUCINE ZIPPER; LEUCINE ZIPPER PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SOLUBLE TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CCL2 PROTEIN, HUMAN; CCR2 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CELL HOMING; CELL MIGRATION; CELL MIGRATION ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; EXPRESSION VECTOR; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN UMBILICAL CORD MESENCHYMAL STEM CELL; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER CELL LINE; LUNG CANCER; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SURVIVAL RATE; TROPISM; TUMOR TROPISM; UMBILICAL CORD; XENOGRAFT; ANIMAL; CELL MOTION; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; LUNG NEOPLASMS; MESENCHYMAL STROMA CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MIGRATION ASSAYS; CELL MOVEMENT; CHEMOKINE CCL2; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUNG NEOPLASMS; MESENCHYMAL STROMAL CELLS; MICE; MOLECULAR TARGETED THERAPY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CCR2; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UMBILICAL CORD;

EID: 84953258168     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4746-7     Document Type: Article

References (39)

1. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7. doi:10.1080/14653240600855905.
2. Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy. 2010;12(5):615–25. doi:10.3109/14653241003631815.
3. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, et al. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med. 2013;11:20. doi:10.1186/1479-5876-11-20.
4. Choi SA, Lee JY, Wang KC, Phi JH, Song SH, Song J, et al. Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. Eur J Cancer. 2012;48(1):129–37. doi:10.1016/j.ejca.2011.04.033.
5. Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood. 2005;106(2):419–27. doi:10.1182/blood-2004-09-3507.
6. Ponte AL, Marais E, Gallay N, Langonne A, Delorme B, Herault O, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells (Dayton, Ohio). 2007;25(7):1737–45. doi:10.1634/stemcells.2007-0054.
7. Wang L, Li Y, Chen J, Gautam SC, Zhang Z, Lu M, et al. Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. Exp Hematol. 2002;30(7):831–6.
8. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5(2):157–63. doi:10.1038/5517.
9. Kim MH, Billiar TR, Seol DW. The secretable form of trimeric TRAIL, a potent inducer of apoptosis. Biochem Biophys Res Commun. 2004;321(4):930–5. doi:10.1016/j.bbrc.2004.07.046.
10. Yan C, Li S, Li Z, Peng H, Yuan X, Jiang L, et al. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin’s lymphoma. Mol Pharm. 2013;10(1):142–51. doi:10.1021/mp300261e.
11. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26(21):3621–30. doi:10.1200/jco.2007.15.7198.
12. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther. 2001;299(1):31–8.
13. Ma L, Feng XY, Cui BL, Law F, Jiang XW, Yang LY, et al. Human umbilical cord Wharton’s jelly-derived mesenchymal stem cells differentiation into nerve-like cells. Chin Med J (Engl). 2005;118(23):1987–93.
14. Danielyan L, Beer-Hammer S, Stolzing A, Schafer R, Siegel G, Fabian C, et al. Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer’s and Parkinson’s disease. Cell Transplant. 2014;23 Suppl 1:S123–39. doi:10.3727/096368914x684970.
15. Prabakar KR, Dominguez-Bendala J, Molano RD, Pileggi A, Villate S, Ricordi C, et al. Generation of glucose-responsive, insulin-producing cells from human umbilical cord blood-derived mesenchymal stem cells. Cell Transplant. 2012;21(6):1321–39. doi:10.3727/096368911x612530.
16. Kang BJ, Kim H, Lee SK, Kim J, Shen Y, Jung S, et al. Umbilical-cord-blood-derived mesenchymal stem cells seeded onto fibronectin-immobilized polycaprolactone nanofiber improve cardiac function. Acta Biomater. 2014;10(7):3007–17. doi:10.1016/j.actbio.2014.03.013.
17. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004;11(14):1155–64. doi:10.1038/sj.gt.3302276.
18. Ren C, Kumar S, Chanda D, Chen J, Mountz JD, Ponnazhagan S. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells (Dayton, Ohio). 2008;26(9):2332–8. doi:10.1634/stemcells.2008-0084.
19. Kanehira M, Xin H, Hoshino K, Maemondo M, Mizuguchi H, Hayakawa T, et al. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther. 2007;14(11):894–903. doi:10.1038/sj.cgt.7701079.
20. Kim SM, Woo JS, Jeong CH, Ryu CH, Lim JY, Jeun SS. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886. Cancer Res. 2012;72(18):4807–17. doi:10.1158/0008-5472.can-12-0123.
21. Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, et al. Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. J Breast Cancer. 2012;15(3):273–82. doi:10.4048/jbc.2012.15.3.273.
22. Mohr A, Albarenque SM, Deedigan L, Yu R, Reidy M, Fulda S, et al. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells (Dayton, Ohio). 2010;28(11):2109–20. doi:10.1002/stem.533.
23. Akimoto K, Kimura K, Nagano M, Takano S, To’a Salazar G, Yamashita T, et al. Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. Stem Cells Dev. 2013;22(9):1370–86. doi:10.1089/scd.2012.0486.
24. Chao KC, Yang HT, Chen MW. Human umbilical cord mesenchymal stem cells suppress breast cancer tumourigenesis through direct cell-cell contact and internalization. J Cell Mol Med. 2012;16(8):1803–15. doi:10.1111/j.1582-4934.2011.01459.x.
25. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer. 2010;9:129. doi:10.1186/1476-4598-9-129.
26. Waterman RS, Henkle SL, Betancourt AM. Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS One. 2012;7(9):e45590. doi:10.1371/journal.pone.0045590.
27. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One. 2010;5(4):e10088. doi:10.1371/journal.pone.0010088.
28. Ringe J, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR, et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem. 2007;101(1):135–46. doi:10.1002/jcb.21172.
29. Takano T, Li YJ, Kukita A, Yamaza T, Ayukawa Y, Moriyama K, et al. Mesenchymal stem cells markedly suppress inflammatory bone destruction in rats with adjuvant-induced arthritis. Lab Invest. 2014;94(3):286–96. doi:10.1038/labinvest.2013.152.
30. Guo J, Zhang H, Xiao J, Wu J, Ye Y, Li Z, et al. Monocyte chemotactic protein-1 promotes the myocardial homing of mesenchymal stem cells in dilated cardiomyopathy. Int J Mol Sci. 2013;14(4):8164–78. doi:10.3390/ijms14048164.
31. Boomsma RA, Geenen DL. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PLoS One. 2012;7(4):e35685. doi:10.1371/journal.pone.0035685.
32. Ryan CM, Brown JA, Bourke E, Prendergast AM, Kavanagh C, Liu Z, et al. ROCK activity and the Gbetagamma complex mediate chemotactic migration of mouse bone marrow-derived stromal cells. Stem Cell Res Ther. 2015;6(1):136. doi:10.1186/s13287-015-0125-y.
33. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res. 2007;13(17):5020–7. doi:10.1158/1078-0432.ccr-07-0731.
34. Belema-Bedada F, Uchida S, Martire A, Kostin S, Braun T. Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2. Cell Stem Cell. 2008;2(6):566–75. doi:10.1016/j.stem.2008.03.003.
35. Rombouts WJ, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia. 2003;17(1):160–70. doi:10.1038/sj.leu.2402763.
36. Shi M, Li J, Liao L, Chen B, Li B, Chen L, et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica. 2007;92(7):897–904.
37. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med. 2003;198(9):1391–402. doi:10.1084/jem.20030267.
38. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012;3:297. doi:10.3389/fimmu.2012.00297.
39. Walczak P, Zhang J, Gilad AA, Kedziorek DA, Ruiz-Cabello J, Young RG, et al. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke. 2008;39(5):1569–74. doi:10.1161/strokeaha.107.502047.